The core activity of DAMIAN PHARMA AG is the development and marketing of pharmaceutical products, in particular the development of therapies for rare diseases such as Primary Aldosteronism (PA).
AI-generated
Offering
Products & services
Industry:Research & DevelopmentPharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Development of targeted therapies for Primary Aldosteronism and other aldosterone-dependent diseases, focusing on diagnosis, localization, and treatment.
Dexfadrostat phosphate (DP13)
Aldosterone synthase inhibitor in clinical development for the medical treatment of Primary Aldosteronism, following Phase I and Phase II studies.
DP14 diagnostic tracer
PET tracer in the research phase for imaging and localization of aldosterone-producing benign tumours without specialized surgery.
Knowledge
No knowledge articles yet
Once DAMIAN PHARMA AG has claimed this profile, we'll publish editorial articles and case studies here together.